HealthDay ReporterLatest Cancer NewsCell Phone Use Might Raise Risk of Brain TumorsChemical Found in Foam Cups a Possible CarcinogenCancer CausesLate-Stage Cancer Patients' Chemo UnjustifiedBankruptcy Risk Doubles After Cancer DiagnosisWant More News? Sign Up for MedicineNet Newsletters!
SUNDAY, June 5 (HealthDay News) -- Two new drugs prolong the lives of patients with advanced melanoma, one of the deadliest forms of skin cancer and one that is notoriously difficult to treat, let alone cure.
The first treatment, vemurafenib, inhibits a gene mutation harbored in half of all melanoma patients, but is not yet approved by the U.S. Food and Drug Administration. The other drug, Yervoy (ipilumumab), is an immune system therapy that won approval in March.
Research on both drugs was presented Sunday at the annual meeting of the American Society of Clinical Oncology in Chicago while also being published simultaneously online in the New England Journal of Medicine.
"This is really a huge step toward personalized care in melanoma," Dr. Paul Chapman, lead author of the first study and the attending physician in the melanoma/sarcoma service at Memorial Sloan-Kettering Cancer Center in New York City, said in a statement. "This
View the Original article
No comments:
Post a Comment